PE20160882A1 - Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal - Google Patents

Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal

Info

Publication number
PE20160882A1
PE20160882A1 PE2016000430A PE2016000430A PE20160882A1 PE 20160882 A1 PE20160882 A1 PE 20160882A1 PE 2016000430 A PE2016000430 A PE 2016000430A PE 2016000430 A PE2016000430 A PE 2016000430A PE 20160882 A1 PE20160882 A1 PE 20160882A1
Authority
PE
Peru
Prior art keywords
bowel syndrome
irritable bowel
antibodies
diagnosis
treatment
Prior art date
Application number
PE2016000430A
Other languages
English (en)
Spanish (es)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20160882(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of PE20160882A1 publication Critical patent/PE20160882A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PE2016000430A 2013-10-09 2014-10-09 Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal PE20160882A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361888658P 2013-10-09 2013-10-09

Publications (1)

Publication Number Publication Date
PE20160882A1 true PE20160882A1 (es) 2016-09-14

Family

ID=52813648

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000430A PE20160882A1 (es) 2013-10-09 2014-10-09 Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal

Country Status (19)

Country Link
US (2) US9851361B2 (enExample)
EP (1) EP3054977B1 (enExample)
JP (1) JP6567509B2 (enExample)
KR (1) KR102259588B1 (enExample)
CN (1) CN105744956B (enExample)
AU (2) AU2014331841B2 (enExample)
BR (1) BR112016007474A2 (enExample)
CA (1) CA2923651C (enExample)
CL (1) CL2016000820A1 (enExample)
ES (1) ES2892905T3 (enExample)
IL (1) IL244971B2 (enExample)
MX (1) MX383423B (enExample)
NZ (1) NZ717633A (enExample)
PE (1) PE20160882A1 (enExample)
PL (1) PL3054977T3 (enExample)
PT (1) PT3054977T (enExample)
RU (1) RU2683781C2 (enExample)
SG (1) SG11201601733VA (enExample)
WO (1) WO2015054529A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
CN105784989A (zh) * 2016-05-17 2016-07-20 上海凯璟生物科技有限公司 一种肠易激综合症标志物CdtB抗体检测试剂盒及其制备方法
CN106053827A (zh) * 2016-05-17 2016-10-26 上海凯璟生物科技有限公司 一种肠易激综合症标志物Vinculin抗体检测试剂盒及其制备方法
US11549146B2 (en) 2016-05-20 2023-01-10 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
RU2763258C1 (ru) * 2020-07-13 2021-12-28 Евгения Николаевна Воронина Способ дифференциальной диагностики воспалительных заболеваний кишечника у детей по комплексу клинико-анамнестических, лабораторных и инструментальных критериев

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20040018528A1 (en) 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP2280285A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
ES2456710T3 (es) 2003-12-05 2014-04-23 Fuso Pharmaceutical Industries Ltd. Genes de toxinas de distensión citoletales como dianas para la detección de bacterias Campylobacter
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
JP2011507509A (ja) 2007-12-20 2011-03-10 インデックス・ダイアグノスティックス・エイビイ Ibdとibsとの区別、ibdの疾患タイプ間の更なる識別における使用する方法およびキット
WO2010060098A1 (en) 2008-11-24 2010-05-27 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
BRPI1008058A8 (pt) 2009-02-11 2018-03-27 Cedars Sinai Medical Center uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
MX383428B (es) * 2012-09-17 2025-03-13 Cedars Sinai Medical Center Determinaciòn de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
KR102259588B1 (ko) 2013-10-09 2021-06-02 세다르스-신나이 메디칼 센터 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
MX384921B (es) 2014-10-09 2025-03-14 Cedars Sinai Medical Center Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
CN106091069A (zh) 2016-06-15 2016-11-09 安徽省绿巨人环境技术有限公司 一种废水再利用装置
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10527621B2 (en) 2009-02-11 2020-01-07 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US9851361B2 (en) 2013-10-09 2017-12-26 Cedars-Sinai Medical Center Methods of comparing anti-vinculin and anti-cytolethal distending toxin antibodies as they relate to irritable bowel syndrome
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
US9851361B2 (en) 2017-12-26
EP3054977B1 (en) 2021-07-21
RU2016116766A (ru) 2017-11-15
MX2016004167A (es) 2016-06-24
KR102259588B1 (ko) 2021-06-02
AU2020203468A1 (en) 2020-06-18
EP3054977A4 (en) 2017-04-12
EP3054977A1 (en) 2016-08-17
AU2014331841B2 (en) 2020-03-12
CA2923651C (en) 2023-03-14
MX383423B (es) 2025-03-14
WO2015054529A1 (en) 2015-04-16
NZ717633A (en) 2021-07-30
PT3054977T (pt) 2021-10-14
US10352944B2 (en) 2019-07-16
US20170038393A1 (en) 2017-02-09
US20180196063A1 (en) 2018-07-12
IL244971B2 (en) 2023-12-01
CN105744956A (zh) 2016-07-06
JP2017502253A (ja) 2017-01-19
SG11201601733VA (en) 2016-04-28
IL244971B1 (en) 2023-08-01
KR20160062161A (ko) 2016-06-01
AU2014331841A1 (en) 2016-03-24
CN105744956B (zh) 2021-07-20
CA2923651A1 (en) 2015-04-16
RU2683781C2 (ru) 2019-04-02
PL3054977T3 (pl) 2021-12-20
BR112016007474A2 (pt) 2017-09-12
ES2892905T3 (es) 2022-02-07
IL244971A0 (en) 2016-05-31
CL2016000820A1 (es) 2016-09-23
HK1221898A1 (zh) 2017-06-16
JP6567509B2 (ja) 2019-08-28

Similar Documents

Publication Publication Date Title
PE20160882A1 (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
BR112015026242A2 (pt) dispositivo de coleta de fluido biológico e sistema de separação e testagem de fluido biológico
MX2018002400A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112015019614A8 (pt) análise de imagens e medições de amostras biológicas
MX2015012437A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
BR112015022490A2 (pt) métodos e composições para classificação de amostras
MX2016013255A (es) Metodos y composiciones para detectar proteinas mal plegadas.
MX2016002537A (es) Anticuerpos y ensayos para la detección del receptor 1 de folato.
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
WO2016198833A3 (en) Methods for analysing a urine sample
MX2016011377A (es) Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo.
BR112015004800A2 (pt) método e aparelho para examinar ovos
MX2017014196A (es) Deteccion de factores de virulencia microbiana bucal.
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
CL2011001944A1 (es) Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs).
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
MX384921B (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
EA201790696A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
GB2545850A (en) System and method using a combined modality optical probe